netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand.  
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Atezolizumab infusion
View adult BNF View SPC online View SMC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Atezolizumab infusion

Atezolizumab infusion (in combination with nab-paclitaxel) is supported for use within the Early Access to Medicines Scheme for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1%

Atezolizumab infusion in combination with bevacizumab, paclitaxel and carboplatin is supported for use for treating advanced non-squamous non-small-cell lung cancer

Consultant Oncologist use only

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017)
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018)
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018)
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019)
   
Cytotoxic Drug Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red

 Patients who require treatment of renal cell carcinoma should be referred to Leeds Teaching Hospital Trust

Axitinib is not stocked at Airedale NHS Foundation Trust

 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015)
   
Brentuximab infusion (Adcetris®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Brentuximab infusion

For treatment of CD30-positive cutaneous T-cell lymphoma in-line after at least one other therapy (second-line) with NICE TA577. 

Consultant Haematologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017)
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017)
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018)
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019)
   
Cytotoxic Drug Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Crizotinib Capsules (Xalkori®)
     


Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  MHRA Drug Safety Update: Crizotinib - risk of cardiac failure (November 2015)
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018)
   
Daratumumab infusion  ( Darzalex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Daratumumab infusion (Darzalex®)

Consultant Haematologist use only. 

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  DSU: Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus (August 2019)
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018)
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019)
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
  • Dasatinib Tablets

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
   
Durvalumab
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Durvalumab Infusion

Supported for treatment of locally advanced non small-cell lung cancer after platinum-based chemo radiation in-line with NICE TA578.

Consultant oncologist use only.

 
Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019)
   
Cytotoxic Drug Eribulin  ( Halaven®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Eribulin Solution for Injection


Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016)
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018)
   
Cytotoxic Drug Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Ibrutinib capsules

Consultant Haematologist use only

Ibrutinib is only available via the CDF. For further information see the link below.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 

 
Link  Cancer Drugs Fund
Link  Drug Safety Update:Ibrutinib: reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017)
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017)
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017)
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
   
Isatuximab infusion (Sarclisa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Isatuximab infusion®

For the treatment of relapsed and refractory myeloma (with pomalidomide and dexamethasone) under MHRA Early Access to medicines Scheme. 

Consultant Haematologist use only.

 

 
   
Cytotoxic Drug Neratinib  (Nerlynx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Niraparib tablets (Nerlynx®)

Approved as an option for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab in-line with provisional NICE recommendations.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
   
Cytotoxic Drug Niraparib (Zejula®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Niraparib Capsules (Zejula®)


Blueteq® registration and approval for use is required for this product before it may be dispensed.

Consultant Oncologist use only

 
Link  TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018)
   
Nivolumab (Opdivo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Nivolumab Infusion

Consultant Oncologist use only.

For use at Specialist Centres only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  DSU: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019)
Link  MHRA Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017)
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017)
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017)
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017)
Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018)
Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019)
Link  TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (May 2019)
   
Cytotoxic Drug Olaparib  (Lynparza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Olaparib capsules - For the treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer in-line with NICE TA381.

 

  • Olaparib tablets - For maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in-line with NICE TA598.

    Consultant Medical Oncologist use only 
 
Link  DSU: Olaparib: Risk of medication errors with new pharmaceutical form (May 2018)
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (August 2019)
Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (January 2020)
Link  SSC2101 - Olaparib 2nd and 3rd line treatment of ovarian, fallopian tube or peritoneal cancer (December 2019)
   
Cytotoxic Drug Pembrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq

For use at specialist centres only in line with NICE TA357 and TA366.

For treating for treating PD-L1-positive non-small-cell lung cancer after chemotherapy in-line with NICE TA428 and NICE TA447.

For locally advanced or metastatic urothelial cancer after platinum-containing therapy in-line with NICE TA519

Consultant Medical Oncologist use only

 

Approved for Hodgkin lymphoma in-line with NICE TA540

Consultant haematologist use only

 

Approved for first-line treatment (in combination with pemetrexed and cisplatin chemotherapy) of metastatic, non-squamous non-small-cell lung cancer in patients with no EGFR or ALK-positive mutations with NICE TA557.

Consultant Oncologist use only

 

Approved for use (in combination with carboplatin and paclitaxel) as an option for untreated metastatic squamous NSCLC in-line with NICE TA600 

Consultant Medical Oncologist use only

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017)
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018)
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018)
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018)
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018)
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only]
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019)
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (September 2019)
Link  NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
   
Pertuzumab  (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq
  • Pertuzumab Infusion

Pertuzumab is also available for some indications via the CDF. For further information see the link below.  

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Cancer Drug Fund
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016)
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019)
   
Cytotoxic Drug Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Ponatinib tablets

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Drug Safety Update: Ponatinib (Iclusig): risk of vascular occlusive events—updated advice on possible dose reduction (April 2017)
Link  DSU: Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome (October 2018)
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017)
   
Cytotoxic Drug Ribociclib (Kisqali®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Ribociclib tablets (Kisqali®)

Approved by D&TC as a treatment option (with fulvestrant) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in-line with NICE TA593

 

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
   
Cytotoxic Drug Rucaparib tablets (Rubraca®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Rucaparib tablets
     

Consultant Oncologist use only

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019)
   
Venetoclax
View adult BNF View SPC online View SMC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Venetoclax film-coated tablets 

Consultant Haemotologist use only.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017)
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019)
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
Cytotoxic Drug Bevacizumab (Avastin®)
(Oncology)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Bevacizumab Infusion

Bevacizumab is only available for via the CDF. For further information see the link below.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Cancer Drug Fund: Bevacizumab
Link  MHRA Drug Safety Update:Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)
Link  NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend]
Link  NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend]
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Bortezomib Injection

Bortezomib is also available for some indications via the CDF list. See link below for further information.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  Cancer Drugs Fund
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007)
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015)
   
Cytotoxic Drug Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Carfilzomib infusion

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  DSU: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events (August 2019)
Link  DSU: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus (November 2019)
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017)
   
Cytotoxic Drug Ixazomib (Ninralo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
BlueTeq
  • Ixazomib capsules

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
   
08.01.05  Expand sub section  Cetuximab
Cytotoxic Drug Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq
  • Cetuximab Infusion

Available via NHSE. See the link below for further information.

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only)
Link  NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED
Link  NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017)
Link  TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Dacarbazine Injection
  • Dacarbazine Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •    
    08.01.05  Expand sub section  Hydroxycarbamide to top
    Cytotoxic Drug Hydroxycarbamide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Hydroxycarbamide Capsules

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •    
    08.01.05  Expand sub section  Ipilimumab
    08.01.05  Expand sub section  Mitotane
    08.01.05  Expand sub section  Panitumumab
    Cytotoxic Drug Panitumumab infusion (Vectibix®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Panitumumab infusion (Vectibix®) 

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
       
    08.01.05  Expand sub section  Pentostatin
    08.01.05  Expand sub section  Platinum compounds to top
    Cytotoxic Drug Carboplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Carboplatin Injection
  • Carboplatin Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •    
    Cytotoxic Drug Cisplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Cisplatin Infusion
  • Cisplatin Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •    
    Cytotoxic Drug Oxaliplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Oxaliplatin Injection
       
     
    Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006)
    Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)
       
    08.01.05  Expand sub section  Porfimer sodium and temoporfin
    08.01.05  Expand sub section  Procarbazine
    Cytotoxic Drug Procarbazine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Procarbazine Capsules

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •    
    08.01.05  Expand sub section  Protein kinase inhibitors
    Abemaciclib tablets  (Verzenios® )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Abemaciclib tablets (Verzenios®)

    Consultant Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
    Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
    Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
       
    Cytotoxic Drug Afatinib (Giotrif®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Afatinib Tablets (Giotrif®)


     
    Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
       
    Cytotoxic Drug Alectinib capsules  (Alecensa®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Alectinib Capsules (Alecensa®)

    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
       
    Cytotoxic Drug Bosutinib (Bosulif®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Bosutinib Tablets

      Consultant Haematologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation(May 2016)
    Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
       
    Cytotoxic Drug Brigatinib tablets (Alunbrig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Brigatinib tablets (Alunbrig®)

    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
       
    Cytotoxic Drug Ceritinib capsules  (Zykadia®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Ceritinib Capsules (Zykadia®)


    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
    Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
       
    Cytotoxic Drug Dacomitinib (Vizimpro®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Dacomitinib Tablets

     

    Consultant Oncology use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019)
       
    Cytotoxic Drug Erlotinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Erlotinib Tablets


     
    Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
    Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
    Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
       
    Cytotoxic Drug Everolimus (Afinitor®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Everolimus Tablets (Afinitor®)

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
    Link  NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
    Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
    Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
       
    Cytotoxic Drug Gefitinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Gefitinib Tablets

     
    Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
    Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
       
    Cytotoxic Drug Idelalisib (Zydelig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Idelalisib Tablets


     
    Link  EMA recommends new safety measures for Zydelig (March 2016)
    Link  MHRA Drug Safety Update: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection (September 2016)
    Link  NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
    Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019)
       
    Cytotoxic Drug Imatinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Imatinib Tablets


     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
    Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
    Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
    Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
       
    Cytotoxic Drug Larotrectinib 20mg/mL oral solution  (Vitrakvi®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Larotrectinib 20mg/mL oral solution (Vitrakvi®)

      Consultant Medical Oncologist use only.

      Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)
       
    Cytotoxic Drug Lorlatinib (Lorviqua®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    NHS England
    BlueTeq
    • Lorlatinib Tablets (Lorviqua®)

             Consultant Medical Oncologist use only.

          Blueteq® registration and approval for use is required for this product before it may be        dispensed.

     
    Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)
       
    Cytotoxic Drug Nilotinib (Tasigna®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Nilotinib Tablets

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
    Link  NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
       
    Cytotoxic Drug Nintedanib capsules  (Vargatef®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Nintedanib Capsules (Vargatef®)


     
    Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
    Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
       
    Cytotoxic Drug Osimertinib mesylate ( Tagrisso®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Osimertinib Tablets

    Consultant Medical Oncologist use only.

     

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
       
    Cytotoxic Drug Palbociclib (Ibrance®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Palbociclib capsules
    • Palbociclib capsules with fulvestrant injection


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
    Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020)
       
    Cytotoxic Drug Ribociclib (Kiskali®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Ribociclib Tablets

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
    Link  TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019)
       
    Cytotoxic Drug Ruxolitinib (Jakavi®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    • Ruxolitinib Tablets


     
    Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
       
    08.01.05  Expand sub section  Taxanes
    Cytotoxic Drug Cabazitaxel (Jevtana®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Cabazitaxel Concentrate for Infusion

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016)
       
    Cytotoxic Drug Docetaxel
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Docetaxel Injection


     
    Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)
    Link  NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
       
    Cytotoxic Drug Paclitaxel
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Paclitaxel Injection
    • Paclitaxel Infusion
    • Paclitaxel as albumin-bound nanoparticles Infusion
       
     
    Link  NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
    Link  NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015)
    Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
    Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003)
       
    08.01.05  Expand sub section  Topoisomerase I inhibitors to top
    Cytotoxic Drug Irinotecan Hydrochloride
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Irinotecan Injection
       
     
    Link  DSU: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events (March 2019)
    Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
    Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017)
       
    Cytotoxic Drug Topotecan
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Topotecan Injection 
       
     
    Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
    Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
    Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
    Link  NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)
       
    08.01.05  Expand sub section  Trabectedin
    08.01.05  Expand sub section  Trastuzumab
    Cytotoxic Drug Trastuzumab (Herceptin® Ontruzant®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Trastuzumab Intravenous Injection (Herceptin®)
    • Trastuzumab Subcutaneous Injection (Herceptin ®)
       
     
    Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)
    Link  NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)
    Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)
       
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Trastuzumab emtansine Powder for Concentrate for Solution for Infusion (Kadcyla®
       
     
    Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017)
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
       
    08.01.05  Expand sub section  Tretinoin
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

    Amber

    Amber - these drugs require specialist initiation or recommendation  

    Amber SCG

    Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

    Red

    Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Red ULM

    Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Grey

    Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

    Black

    Black - Drugs not routinely commissioned so should not usually be prescribed  

    netFormulary